Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Beyond the Hype: Measuring True Enterprise AI Agent Adoption

    As enterprises race to tout AI agent adoption, the real question is whether these tools are driving measurable productivity gains or simply fueling the hype cycle.

    Read more

  • Monaco Enterprises Has Been Acquired by Perimeter Solutions

    William Blair acted as the exclusive financial advisor to Monaco Enterprises, Inc., a portfolio company of Dauntless Capital Partners and Lometa Capital Partners, in connection with its sale to Perimeter Solutions, Inc. (NYSE: PRM).

    Read more

  • Economics Weekly: Let the Market Decide

    One of the key points that came out of last week’s FOMC meeting was that Fed Chair Kevin Warsh wants the bond market to do more of the heavy lifting with regard to fighting inflation and promoting economic growth.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures